APOB and familial hypercholesterolemia: Moreover the successful use of a type of carrier system for a certain disease does not guarantee its efficiency for the treatment of another illness, i.e., the phase I clinical trial of TKM-ApoB formulation based on LNP technology, and containing an siRNA targeting ApoB to be used for the treatment of hypercholesterolemia, was terminated due to patients’ immune systems stimulation, as well as another Tekmira Pharmaceutical product developed to combat the Ebola Virus (TKM-100802).